Literature DB >> 9416836

An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.

S McCracken1, C S Kim, Y Xu, M Minden, N G Miyamoto.   

Abstract

The lymphoid-specific protein tyrosine kinase, p56lck which is essential for both T cell development and function, is aberrantly expressed in colon and small lung carcinoma lines. In this paper, we demonstrate p56lck is also expressed in colon tumour biopsies due predominantly or exclusively to the use of the lck type I promoter. In T leukaemia lines, the lck type I promoter requires binding sites for both Ets- and Myb-related transcription factors. In contrast, in colon tumour lines the activation of the lck type I promoter requires the Ets but not the Myb binding site. In these lines, a consensus binding site for HMG-related transcription factors, AACAAAG, is required for efficient lck type I promoter activity. Sox-4 is a candidate transcription factor for binding and activating the lck type l promoter in colon carcinoma cells. Co-expression of Ets-1 and Sox-4, but neither protein alone, was sufficient to activate the lck type l promoter in HeLa cells which do not normally express lck transcripts. These results suggest that aberrant expression of p56lck from the lck type l promoter in colon carcinoma arises from transcriptional activation mediated by Ets- and HMG-related transcription factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416836     DOI: 10.1038/sj.onc.1201474

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.

Authors:  Kathryn E Boyd; Ying-Yi Xiao; Kai Fan; Amanda Poholek; Neal G Copeland; Nancy A Jenkins; Archibald S Perkins
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor).

Authors:  C Li; B Bapat; B A Alman
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

4.  Differential expression of SOX4 and SOX11 in medulloblastoma.

Authors:  Ching-Jung Lee; Vanessa J Appleby; Alex T Orme; Wai-In Chan; Paul J Scotting
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.

Authors:  Parham Ramezani-Rad; Huimin Geng; Christian Hurtz; Lai N Chan; Zhengshan Chen; Hassan Jumaa; Ari Melnick; Elisabeth Paietta; William L Carroll; Cheryl L Willman; Véronique Lefebvre; Markus Müschen
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

6.  Integrated classification of lung tumors and cell lines by expression profiling.

Authors:  Carl Virtanen; Yuichi Ishikawa; Daisuke Honjoh; Mami Kimura; Miyuki Shimane; Tatsu Miyoshi; Hitoshi Nomura; Michael H Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

Review 7.  Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis.

Authors:  Seyed Mehdi Jafarnejad; Gholamreza Safaee Ardekani; Mazyar Ghaffari; Gang Li
Journal:  Cell Mol Life Sci       Date:  2012-10-19       Impact factor: 9.261

8.  Connections between ETV6-modulated genes: identification of shared features.

Authors:  Gino Boily; Patrick Beaulieu; Jasmine Healy; Daniel Sinnett
Journal:  Cancer Inform       Date:  2008-04-21

9.  Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.

Authors:  M Naito; Y Komohara; Y Ishihara; M Noguchi; Y Yamashita; T Shirakusa; A Yamada; K Itoh; M Harada
Journal:  Br J Cancer       Date:  2007-11-27       Impact factor: 7.640

10.  Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice.

Authors:  Jeffrey Chou; Matthew P Fitzgibbon; Christie-Lynn L Mortales; Andrea M H Towlerton; Melissa P Upton; Raymond S Yeung; Martin W McIntosh; Edus H Warren
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.